Inovio Pharmaceuticals Inc (INO)

[desarcmo]

More from todays INO announcement:

"interim immune responses and safety results expected in late June."

"The Phase 1 study is designed to assess the safety profile and immunogenicity of INO-4800 in support of advancing rapidly to a Phase 2/3 efficacy trial, which is planned to potentially initiate this summer. "

If interim response is anything near previous trials on SAR virus this will be a knockout. I expect additional funding or partnerships to appear either prior to or at these result releases. After that sky the limit. Don't forget, cancer Phase 3 trial results release later this year too. As Dr. Kim said, 2020 will be a transformational year for INO.